Journal of Clinical Endocrinology & Metabolism, Vol 78, 1128-1134, Copyright © 1994 by Endocrine Society

ARTICLES

Negative feedback of atrial natriuretic peptides

DL Vesely, MA Douglass, JR Dietz, AT Giordano, MT McCormick, G Rodriguez-Paz and DD Schocken
Department of Medicine, University of South Florida Health Sciences Center, Tampa.

The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1-30 [i.e. pro-ANF-(1- 30)], 31-67 [i.e. pro-ANF(31-67)], 79-98 [i.e. pro-ANF-(79-98)], and 99- 126 [i.e. atrial natriuretic factor (ANF)] of 126-amino acid ANF prohormone have a negative feedback on their own and each others' release. Thirty healthy human subjects were studied with infusion of 100 ng/kg BW.min for 60 min of each of the respective peptides. Pro-ANF- (1-30) decreased the circulating concentrations of pro-ANF-(31-67) and ANF 51% and 89%, respectively. Pro-ANF-(31-67) decreased the circulating concentration of ANF by 55% and the peptides immunologically recognized by the pro-ANF-(1-30) RIA by 58% [this assay recognizes pro-ANF-(1-30) (50%) and pro-ANF-(1-98) (50%)]. Pro-ANF-(79- 98) decreased the circulating concentration of ANF by 40%, pro-ANF-(31- 67) by 31%, and the peptides recognized by the pro-ANF-(1-30) RIA by 46%. ANF decreased the circulating concentration of pro-ANF-(31-67) by 40% and the peptides recognized by pro-ANF-(1-30) RIA by 38%. Infusion of pro-ANF-(1-30), -(31-67), -(79-98), and -(99-126) also decreased the excretion of the other atrial natriuretic peptides measured in the urine by 32-84%. Infusion of vehicle only did not result in any decrease in these atrial natriuretic peptides in either plasma or urine. These data taken together indicate that each of the respective atrial natriuretic peptides inhibits the release, rather than breakdown, of each other, as increased breakdown would have resulted in their urinary concentrations being increased. This study further indicates that because pro-ANF-(1-98) was decreased in the circulation secondary to pro-ANF-(31-67) and pro-ANF-(79-98) infusions, they inhibit their own release, as they are both derived from pro-ANF-(1-98).

This article has been cited by other articles:

				M. Weber, M. Burian, I. Dragutinovic, H. Moellmann, H. Nef, A. Elsaesser, V. Mitrovic, C. Hamm, and G. Geisslinger Genetic polymorphism of the type A human natriuretic peptide receptor (NPR-A) gene contributes to the interindividual variability in the BNP system Eur J Heart Fail, May 1, 2008; 10(5): 482 - 489. [Abstract] [Full Text] [PDF]

				S. R. Saba, A. H. Garces, L. C. Clark, J. Soto, W. R. Gower Jr., and D. L. Vesely Immunocytochemical Localization of Atrial Natriuretic Peptide, Vessel Dilator, Long-acting Natriuretic Peptide, and Kaliuretic Peptide in Human Pancreatic Adenocarcinomas J. Histochem. Cytochem., August 1, 2005; 53(8): 989 - 995. [Abstract] [Full Text] [PDF]

				J. R. Dietz, C. S. Landon, S. J. Nazian, D. L. Vesely, and W. R. Gower Jr. Effects of Cardiac Hormones on Arterial Pressure and Sodium Excretion in NPRA Knockout Mice Experimental Biology and Medicine, September 1, 2004; 229(8): 813 - 818. [Abstract] [Full Text] [PDF]

				H. Patel, J. R. Dietz, A. Owen, G. S. Miguel, M. T. McCormick, D. D. Schocken, and D. L. Vesely Combined Treatment with Vessel Dilator and Kaliuretic Hormone in Persons with Congestive Heart Failure Experimental Biology and Medicine, June 1, 2004; 229(6): 521 - 527. [Abstract] [Full Text] [PDF]

				D. L. Vesely Natriuretic peptides and acute renal failure Am J Physiol Renal Physiol, August 1, 2003; 285(2): F167 - F177. [Abstract] [Full Text] [PDF]

				D. L. Vesely, G. I. San Miguel, I. Hassan, and D. D. Schocken Atrial Natriuretic Hormone, Vessel Dilator, Long-Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease the Circulating Concentrations of CRH, Corticotropin, and Cortisol J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4244 - 4249. [Abstract] [Full Text] [PDF]

				D. L Vesely Atrial natriuretic peptides in pathophysiological diseases Cardiovasc Res, September 1, 2001; 51(4): 647 - 658. [Full Text] [PDF]

				M. D. Vesely, W. R. Gower Jr., G. Perez-Lamboy, R. M. Overton, L. Graddy, and D. L. Vesely Evidence for an Atrial Natriuretic Peptide-Like Gene in Plants Experimental Biology and Medicine, January 1, 2001; 226(1): 61 - 65. [Abstract] [Full Text]

				L. C. Clark, H. Farghaly, S. R. Saba, and D. L. Vesely Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1555 - H1564. [Abstract] [Full Text] [PDF]

				S. J. Lee, S. Z. Kim, X. Cui, S. H. Kim, K. S. Lee, Y. J. Chung, and K. W. Cho C-type natriuretic peptide inhibits ANP secretion and atrial dynamics in perfused atria: NPR-B-cGMP signaling Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H208 - H221. [Abstract] [Full Text] [PDF]

				D. L. Vesely, J. R. Dietz, J. R. Parks, M. Baig, M. T. McCormick, G. Cintron, and D. D. Schocken Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure Circulation, July 28, 1998; 98(4): 323 - 329. [Abstract] [Full Text] [PDF]

				B. H. Ackerman, R. M. Overton, M. T. McCormick, D. D. Schocken, and D. L. Vesely Disposition of Vessel Dilator and Long-Acting Natriuretic Peptide in Healthy Humans after a One-Hour Infusion J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 603 - 608. [Abstract] [Full Text]

				H. Leskinen, O. Vuolteenaho, M. Toth, and H. Ruskoaho Atrial Natriuretic Peptide (ANP) Inhibits Its Own Secretion via ANPA Receptors: Altered Effect in Experimental Hypertension Endocrinology, May 1, 1997; 138(5): 1893 - 1902. [Abstract] [Full Text] [PDF]